{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:35Z","timestamp":1790821955681,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.tibtech.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:30:40Z","timestamp":1785213040000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A rapid and high-throughput biotechnology quantifies major glycoforms of human IgG1 mAb drugs"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-2616","authenticated-orcid":false,"given":"Yasuyuki","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-8744","authenticated-orcid":false,"given":"Shiho","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7754-6570","authenticated-orcid":false,"given":"Wenyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Biel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica J.","family":"Fratz-Berilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1700-357X","authenticated-orcid":false,"given":"Uriel","family":"Ortega-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tylee","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-4619","authenticated-orcid":false,"given":"Alexis Q.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Namuswe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-8049","authenticated-orcid":false,"given":"V. Ashutosh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Kirshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-5439","authenticated-orcid":false,"given":"Yoshiki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-1976","authenticated-orcid":false,"given":"Tongzhong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.07.004_bb0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/molecules30030482","article-title":"The pharmaceutical industry in 2024: an analysis of the FDA drug approvals from the perspective of molecules","volume":"30","author":"de la Torre","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0010","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/BA20090363","article-title":"Engineering mammalian cells in bioprocessing \u2013 current achievements and future perspectives","volume":"55","author":"Lim","year":"2010","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrd2804","article-title":"Glycosylation as a strategy to improve antibody-based therapeutics","volume":"8","author":"Jefferis","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jbiotec.2017.04.028","article-title":"Therapeutic glycoprotein production in mammalian cells","volume":"251","author":"Lalonde","year":"2017","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/glycob\/cwz065","article-title":"The history of IgG glycosylation and where we are now","volume":"30","author":"Cobb","year":"2020","journal-title":"Glycobiology"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00216-014-8108-x","article-title":"Post-translational structural modifications of immunoglobulin G and their effect on biological activity","volume":"407","author":"Hmiel","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0045","doi-asserted-by":"crossref","first-page":"20167","DOI":"10.1073\/pnas.0809257105","article-title":"Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors","volume":"105","author":"Sazinsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.818736","article-title":"Sialylation as an important regulator of antibody function","volume":"13","author":"Vattepu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0060","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1038\/s41598-023-31195-6","article-title":"Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG","volume":"13","author":"Matsumoto","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0065","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3 RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/bit.20151","article-title":"Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"87","author":"Yamane-Ohnuki","year":"2004","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0075","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/19420862.2018.1551044","article-title":"Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms","volume":"11","author":"Wada","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0080","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fimmu.2017.00877","article-title":"Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities","volume":"8","author":"Dekkers","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0085","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4161\/mabs.20450","article-title":"Increased serum clearance of oligomannose species present on a human IgG1 molecule","volume":"4","author":"Alessandri","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/138920108786786411","article-title":"Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins","volume":"9","author":"Beck","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100891","article-title":"N-glycans as functional effectors of genetic and epigenetic disease risk","volume":"79","author":"Stambuk","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2009.04.007","article-title":"Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action","volume":"30","author":"Jefferis","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0130","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.tibtech.2016.02.013","article-title":"N-glycosylation design and control of therapeutic monoclonal antibodies","volume":"34","author":"Sha","year":"2016","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40259-020-00407-0","article-title":"Demonstrating analytical similarity of trastuzumab biosimilar HLX02 to Herceptin\u00ae with a panel of sensitive and orthogonal methods including a novel Fc\u03b3RIIIa affinity chromatography technology","volume":"34","author":"Xie","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0140","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1083\/jcb.200207155","article-title":"Sweet solution: sugars to the rescue","volume":"158","author":"Freeze","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/bit.22812","article-title":"An investigation of intracellular glycosylation activities in CHO cells: effects of nucleotide sugar precursor feeding","volume":"107","author":"Wong","year":"2010","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0155","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1074\/mcp.M114.039537","article-title":"Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes","volume":"13","author":"Bondt","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.010090","article-title":"High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations","volume":"10","author":"Pucic","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nchembio.511","article-title":"NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic","volume":"7","author":"Barb","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.113035","article-title":"Analysis of cetuximab N-glycosylation using multiple fractionation methods and capillary electrophoresis mass spectrometry","volume":"180","author":"Varadi","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0175","doi-asserted-by":"crossref","first-page":"13569","DOI":"10.1021\/acs.analchem.5c02033","article-title":"Hydrophilic interaction chromatography HRMS with acrylamide monolithic columns: a novel approach for intact antibody glycoform characterization","volume":"97","author":"van der Zon","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","article-title":"The impact of glycosylation on the biological function and structure of human immunoglobulins","volume":"25","author":"Arnold","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0185","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1177\/0961203316640368","article-title":"Sweet but dangerous \u2013 the role of immunoglobulin G glycosylation in autoimmunity and inflammation","volume":"25","author":"Biermann","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0190","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.str.2015.06.015","article-title":"The structural role of antibody N-glycosylation in receptor interactions","volume":"23","author":"Subedi","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0195","doi-asserted-by":"crossref","first-page":"9868","DOI":"10.1073\/pnas.1307864110","article-title":"General mechanism for modulating immunoglobulin effector function","volume":"110","author":"Sondermann","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0200","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/ijms19041076","article-title":"Lectin-binding specificity of the fertilization-relevant protein PDC-109 by means of surface plasmon resonance and carbohydrate recognition domain excision-mass spectrometry","volume":"19","author":"Defaus","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0205","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1039\/D2CS00954D","article-title":"Glycomimetics for the inhibition and modulation of lectins","volume":"52","author":"Leusmann","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0210","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acschembio.1c00689","article-title":"A useful guide to lectin binding: machine-learning directed annotation of 57 unique lectin specificities","volume":"17","author":"Bojar","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0215","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbagen.2005.11.021","article-title":"Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis","volume":"1760","author":"Holland","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0220","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4049\/jimmunol.1502136","article-title":"The emerging importance of IgG Fab glycosylation in immunity","volume":"196","author":"van de Bovenkamp","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0225","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-62703-327-5_7","article-title":"Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry","volume":"988","author":"Janin-Bussat","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0230","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/pbi.12137","article-title":"Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco","volume":"12","author":"Teh","year":"2014","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0235","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/glycob\/cwv047","article-title":"EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans","volume":"25","author":"Sjogren","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0240","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/glycob\/10.5.477","article-title":"Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics","volume":"10","author":"Raju","year":"2000","journal-title":"Glycobiology"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/15321819308019846","article-title":"Quantitative analysis of immunoglobulin G subclasses in the rat","volume":"14","author":"Kinoshita","year":"1993","journal-title":"J. Immunoass."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0250","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/bit.70016","article-title":"A surface plasmon resonance-based integrated assay for quantification and glycosylation characterization of monoclonal antibodies in crude heterogeneous samples","volume":"122","author":"Metayer","year":"2025","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0255","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/bit.28673","article-title":"A low-temperature SPR-based assay for monoclonal antibody galactosylation and fucosylation assessment using Fc\u03b3RIIA\/B","volume":"121","author":"Gaudreault","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0260","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/btpr.2305","article-title":"Controlling the time evolution of mAb N-linked glycosylation, part I: microbioreactor experiments","volume":"32","author":"Villiger","year":"2016","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0265","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/btpr.2315","article-title":"Controlling the time evolution of mAb N-linked glycosylation - part II: model-based predictions","volume":"32","author":"Villiger","year":"2016","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0270","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/bp000026u","article-title":"Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors","volume":"16","author":"Kunkel","year":"2000","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0275","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/bit.10673","article-title":"Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24","volume":"83","author":"Muthing","year":"2003","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0280","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/glycob\/cwp079","article-title":"Optimal and consistent protein glycosylation in mammalian cell culture","volume":"19","author":"Hossler","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0285","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4161\/mabs.2.5.12720","article-title":"Cell culture processes for monoclonal antibody production","volume":"2","author":"Li","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2505088","article-title":"Process development for production of non-originator NISTmAb from CHO and NS0 cell lines","volume":"17","author":"Fratz-Berilla","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0295","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.isci.2019.01.006","article-title":"Dissecting N-glycosylation dynamics in chinese hamster ovary cells fed-batch cultures using time course omics analyses","volume":"12","author":"Sumit","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0300","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1021\/acs.analchem.0c00185","article-title":"Comparative elucidation of cetuximab heterogeneity on the intact protein level by cation exchange chromatography and capillary electrophoresis coupled to mass spectrometry","volume":"92","author":"Fussl","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0305","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0310","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4161\/mabs.24981","article-title":"Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies","volume":"5","author":"Schlothauer","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1429600","article-title":"In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics","volume":"15","author":"Saporiti","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fmolb.2019.00057","article-title":"The structural complexity and animal tissue distribution of N-glycolylneuraminic acid (Neu5Gc)-terminated glycans. Implications for their immunogenicity in clinical xenografting","volume":"6","author":"Breimer","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jim.2012.05.022","article-title":"Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc","volume":"382","author":"Anumula","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0330","series-title":"Essentials of Glycobiology","article-title":"Antibodies and lectins in glycan analysis","author":"Cummings","year":"2009"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0335","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0340","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0345","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0350","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1038\/s41596-024-01011-0","article-title":"The HADDOCK2.4 web server for integrative modeling of biomolecular complexes","volume":"19","author":"Honorato","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105365","article-title":"A highly specific antibody against the core fucose of the N-glycan in IgG identifies the pulmonary diseases and its regulation by CCL2","volume":"299","author":"Kanto","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0360","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/s41467-023-38453-1","article-title":"Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody","volume":"14","author":"Gupta","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.2864","article-title":"Lectin bio-layer interferometry for assessing product quality of Fc- glycosylated immunoglobulin G","volume":"35","author":"Wallner","year":"2019","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0370","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41467-025-67070-3","article-title":"Asymmetrically glycosylated IgG1 antibodies are universal and drive human disease","volume":"17","author":"Azzam","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0375","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.copbio.2009.10.008","article-title":"Expression systems for therapeutic glycoprotein production","volume":"20","author":"Durocher","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0380","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jbiotec.2007.04.025","article-title":"Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics","volume":"130","author":"Kanda","year":"2007","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0385","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/bit.26188","article-title":"FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality","volume":"114","author":"Louie","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0390","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/glycob\/cws064","article-title":"Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant","volume":"22","author":"Zhang","year":"2012","journal-title":"Glycobiology"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108169","article-title":"IgG glycans in health and disease: prediction, intervention, prognosis, and therapy","volume":"67","author":"Shkunnikova","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0400","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41590-024-01916-8","article-title":"A unique serum IgG glycosylation signature predicts development of Crohn\u2019s disease and is associated with pathogenic antibodies to mannose glycan","volume":"25","author":"Gaifem","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0405","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.aai8128","article-title":"IgG antibodies to dengue enhanced for Fc\u03b3RIIIA binding determine disease severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0410","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1172\/JCI65708","article-title":"Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity","volume":"123","author":"Ackerman","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0415","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2337\/dc22-0833","article-title":"Immunoglobulin G N-glycosylation signatures in incident type 2 diabetes and cardiovascular disease","volume":"45","author":"Birukov","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8378","article-title":"Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity","volume":"371","author":"Larsen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41590-020-00828-7","article-title":"Proinflammatory IgG Fc structures in patients with severe COVID-19","volume":"22","author":"Chakraborty","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0435","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","article-title":"Immunoglobulin G glycosylation in aging and diseases","volume":"333","author":"Gudelj","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0440","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/gerona\/glt190","article-title":"Glycans are a novel biomarker of chronological and biological ages","volume":"69","author":"Kristic","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0445","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of macromolecular assemblies from crystalline state","volume":"372","author":"Krissinel","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278294","article-title":"SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins","volume":"17","author":"Matthews","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0455","article-title":"A chemoenzymatic method for simultaneous profiling N- and O-glycans on glycoproteins using one-pot format","volume":"4","author":"Ortega-Rodriguez","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.104336","article-title":"Protocol for simultaneous profiling of N- and O-glycans on glycoproteins using a one-pot format","volume":"7","author":"Knizner","year":"2026","journal-title":"STAR Protoc."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0465","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1038\/ncomms9072","article-title":"Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria","volume":"6","author":"Robinson","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.07.004_bb0470","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/bi00512a001","article-title":"Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution","volume":"20","author":"Deisenhofer","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.tibtech.2026.07.004_bb0475","doi-asserted-by":"crossref","first-page":"D301","DOI":"10.1093\/nar\/gkp946","article-title":"IMGT\/3Dstructure-DB and IMGT\/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF","volume":"38","author":"Ehrenmann","year":"2010","journal-title":"Nucleic Acids Res."}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926002830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926002830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:26:02Z","timestamp":1786217162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926002830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":95,"alternative-id":["S0167779926002830"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.07.004","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rapid and high-throughput biotechnology quantifies major glycoforms of human IgG1 mAb drugs","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}